Celo provide secure smartphone comms for cancer researchers

Celo, a startup that has developed a secure messaging system for the healthcare industry, is partnering with pharmaceutical company Roche NZ

Celo, a startup that has developed a secure messaging system for the healthcare industry, is partnering with pharmaceutical company Roche NZ to provide a secure messaging service that will enable oncology practitioners to communicate and share information via smartphones and tablets.

Celo says its partnership with Roche NZ will facilitate the introduction of the Celo healthcare secure messaging platform (Celo App) to research and clinical professionals active in oncology, including GPs and nurses, through the Smart Oncology Network (SONet), a collaboration between the New Zealand Society for Oncology (NZSO), Roche NZ and Celo.

Roche NZ will make the Celo App available free for some NZSO members to pilot this year.

NZSO president Ben Lawrence explained that, today, cancer research is conducted by multidisciplinary teams of clinicians and scientists around the country. “We need a tool that enables us to communicate to the whole team in real-time, and still keep each patient's data 100 percent safe,” he said.

Celo says it “supplies healthcare-grade, encrypted, industry-compliant secure and real-time messaging for healthcare … developed by healthcare professionals from the ground up and … specially designed for easy use in a clinical setting.”

Users of the Celo App “can communicate with each other, send documents and photographs, and safely share patient details within a secure, encrypted, NZ Ministry of Health-approved, digital network.”

Celo says the genesis of the collaboration was NZSO asking industry stakeholders to come up with new ways to leverage the outputs of NZ cancer research groups, leading Roche NZ to explore the potential for digital communication.

Roche NZ, medical manager, Dr Stuart Ryan, said that, after extensive research, it had decided Celo was best suited to provide  a digital tool to improve communication between oncologists and members of their translational research teams.

Celo CEO Steve Vlok said district health boards in New Zealand might join Celo and provide secure communication for their clinicians to reduce the risk of patient information, including images, being exchanged on personal phones.

Celo was founded in 2014, and in 2015 partnered with the Canterbury District Health Board to develop its secure messaging product.

 

 

Join the newsletter!

Error: Please check your email address.

More about CanterburyRocheSmart

Show Comments

Market Place

[]